Literature DB >> 28615337

Accumulation of methylglyoxal increases the advanced glycation end-product levels in DRG and contributes to lumbar disk herniation-induced persistent pain.

Cui-Cui Liu1, Xin-Sheng Zhang1, Yu-Ting Ruan1, Zhu-Xi Huang1, Su-Bo Zhang1, Meng Liu2, Hai-Jie Luo1, Shao-Ling Wu1, Chao Ma3.   

Abstract

Lumbar disk herniation (LDH) with discogenic low back pain and sciatica is a common and complicated musculoskeletal disorder. The underlying mechanisms are poorly understood, and there are no effective therapies for LDH-induced pain. In the present study, we found that the patients who suffered from LDH-induced pain had elevated plasma methylglyoxal (MG) levels. In rats, implantation of autologous nucleus pulposus (NP) to the left lumbar 5 spinal nerve root, which mimicked LDH, induced mechanical allodynia, increased MG level in plasma and dorsal root ganglion (DRG), and enhanced the excitability of small DRG neurons (<30 μm in diameter). Intrathecal injection of MG also induced mechanical allodynia, and its application to DRG neurons ex vivo increased the number of action potentials evoked by depolarizing current pulses. Furthermore, inhibition of MG accumulation by aminoguanidine attenuated the enhanced excitability of small DRG neurons and the mechanical allodynia induced by NP implantation. In addition, NP implantation increased levels of advanced glycation end products (AGEs) in DRG, and intrathecal injection of MG-derived AGEs induced the mechanical allodynia and DRG neuronal hyperactivity. Intrathecal injection of MG also significantly increased the expression of AGEs in DRG. Importantly, scavenging of MG by aminoguanidine also attenuated the increase in AGEs induced by NP implantation. These results suggested that LDH-induced MG accumulation contributed to persistent pain by increasing AGE levels. Thus generation of AGEs from MG may represent a target for treatment of LDH-induced pain.NEW &amp; NOTEWORTHY Our study demonstrates that methylglyoxal accumulation via increasing advanced glycation end-product levels in dorsal root ganglion contributes to the persistent pain induced by lumbar disk herniation, which proposed potential targets for the treatment of lumbar disk herniation-induced persistent pain.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  AGEs; DRG; lumbar disk herniation; methylglyoxal; pain

Mesh:

Substances:

Year:  2017        PMID: 28615337      PMCID: PMC5558033          DOI: 10.1152/jn.00745.2016

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  42 in total

1.  Cytokine expression in the epidural space: a model of noncompressive disc herniation-induced inflammation.

Authors:  Jason M Cuéllar; Paula M Borges; Vanessa Gabrovsky Cuéllar; Andrew Yoo; Gaetano J Scuderi; David C Yeomans
Journal:  Spine (Phila Pa 1976)       Date:  2013-01-01       Impact factor: 3.468

2.  Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.

Authors:  Naila Ahmed; Usman Ahmed; Paul J Thornalley; Klaus Hager; Gerd Fleischer; Gerald Münch
Journal:  J Neurochem       Date:  2005-01       Impact factor: 5.372

Review 3.  Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases.

Authors:  M A Grillo; S Colombatto
Journal:  Amino Acids       Date:  2007-11-16       Impact factor: 3.520

4.  Contribution of chemokine CCL2/CCR2 signaling in the dorsal root ganglion and spinal cord to the maintenance of neuropathic pain in a rat model of lumbar disc herniation.

Authors:  Xiang Zhu; Su Cao; Ming-Di Zhu; Jin-Qian Liu; Jun-Jie Chen; Yong-Jing Gao
Journal:  J Pain       Date:  2014-01-23       Impact factor: 5.820

5.  Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurons: synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases.

Authors:  S Kikuchi; K Shinpo; F Moriwaka; Z Makita; T Miyata; K Tashiro
Journal:  J Neurosci Res       Date:  1999-07-15       Impact factor: 4.164

6.  Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products.

Authors:  Narkunaraja Shanmugam; Young Sook Kim; Linda Lanting; Rama Natarajan
Journal:  J Biol Chem       Date:  2003-06-30       Impact factor: 5.157

7.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

Review 8.  Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress.

Authors:  Julio C Tóbon-Velasco; Elvis Cuevas; Mónica A Torres-Ramos
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

Review 9.  Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.

Authors:  Velandai Srikanth; Annette Maczurek; Thanh Phan; Megan Steele; Bernadette Westcott; Damian Juskiw; Gerald Münch
Journal:  Neurobiol Aging       Date:  2009-05-22       Impact factor: 4.673

Review 10.  Role of methylglyoxal in Alzheimer's disease.

Authors:  Cristina Angeloni; Laura Zambonin; Silvana Hrelia
Journal:  Biomed Res Int       Date:  2014-03-09       Impact factor: 3.411

View more
  7 in total

1.  Methylglyoxal and a spinal TRPA1-AC1-Epac cascade facilitate pain in the db/db mouse model of type 2 diabetes.

Authors:  Ryan B Griggs; Diogo F Santos; Don E Laird; Suzanne Doolen; Renee R Donahue; Caitlin R Wessel; Weisi Fu; Ghanshyam P Sinha; Pingyuan Wang; Jia Zhou; Sebastian Brings; Thomas Fleming; Peter P Nawroth; Keiichiro Susuki; Bradley K Taylor
Journal:  Neurobiol Dis       Date:  2019-02-23       Impact factor: 5.996

2.  The Type 2 Diabetes Factor Methylglyoxal Mediates Axon Initial Segment Shortening and Alters Neuronal Function at the Cellular and Network Levels.

Authors:  Ryan B Griggs; Duc V M Nguyen; Leonid M Yermakov; Jeneane M Jaber; Jennae N Shelby; Josef K Steinbrunner; John A Miller; Carlos Gonzalez-Islas; Peter Wenner; Keiichiro Susuki
Journal:  eNeuro       Date:  2021-10-06

3.  Activation of the integrated stress response in nociceptors drives methylglyoxal-induced pain.

Authors:  Paulino Barragán-Iglesias; Jasper Kuhn; Guadalupe C Vidal-Cantú; Ana Belen Salinas-Abarca; Vinicio Granados-Soto; Gregory O Dussor; Zachary T Campbell; Theodore J Price
Journal:  Pain       Date:  2019-01       Impact factor: 7.926

4.  Methylglyoxal Requires AC1 and TRPA1 to Produce Pain and Spinal Neuron Activation.

Authors:  Ryan B Griggs; Don E Laird; Renee R Donahue; Weisi Fu; Bradley K Taylor
Journal:  Front Neurosci       Date:  2017-12-06       Impact factor: 4.677

5.  Methylglyoxal Disrupts Paranodal Axoglial Junctions via Calpain Activation.

Authors:  Ryan B Griggs; Leonid M Yermakov; Domenica E Drouet; Duc V M Nguyen; Keiichiro Susuki
Journal:  ASN Neuro       Date:  2018 Jan-Dec       Impact factor: 4.146

Review 6.  Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain.

Authors:  Muhammad Saad Yousuf; Stephanie I Shiers; James J Sahn; Theodore J Price
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 7.  TRPA1 as a therapeutic target for nociceptive pain.

Authors:  Daniel Souza Monteiro de Araujo; Romina Nassini; Pierangelo Geppetti; Francesco De Logu
Journal:  Expert Opin Ther Targets       Date:  2020-09-11       Impact factor: 6.902

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.